Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19235854rdf:typepubmed:Citationlld:pubmed
pubmed-article:19235854lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:19235854lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:19235854lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19235854lifeskim:mentionsumls-concept:C0004561lld:lifeskim
pubmed-article:19235854lifeskim:mentionsumls-concept:C0024314lld:lifeskim
pubmed-article:19235854lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:19235854lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:19235854pubmed:issue4lld:pubmed
pubmed-article:19235854pubmed:dateCreated2009-3-2lld:pubmed
pubmed-article:19235854pubmed:abstractTextInfection with hepatitis C virus (HCV) is associated with lymphoproliferative disorders, represented by essential mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma, but the pathogenic mechanism remains obscure. HCV may infect B cells or interact with their cell surface receptors, and induce lymphoproliferation. The influence of HCV infection of B cells on the development of lymphoproliferative disorders was evaluated in 75 patients with persistent HCV infection. HCV infection was more prevalent (63% vs. 16%, 14%, or 17% P < 0.05 for each), and HCV RNA levels were higher (3.35 +/- 3.85 vs. 1.75 +/- 2.52, 2.15 +/- 2.94 or 2.10 +/- 2.90 log copies/100 ng, P < 0.01 for each) in B cells than CD4(+), CD8(+) T cells or other cells. Negative-strand HCV RNA, as a marker of viral replication, was detected in B cells from four of the 75 (5%) patients. Markers for lymphoproliferative disorders were more frequent in the 50 patients with chronic hepatitis C than the 32 with chronic hepatitis B, including cryoglobulinemia (26% vs. 0%, P < 0.001), low CH(50) levels (48% vs. 3%, P = 0.012), and the clonality of B cells (12% vs. 0%, P < 0.01). By multivariate analysis, HCV RNA in B cells was an independent factor associated with the presence of at least one marker for lymphoproliferation (odds ratio: 1.98 [95% confidence interval: 1.36-7.24], P = 0.027). Based on the results obtained, the infection of B cells with HCV would play an important role in the development of lymphoproliferative disorders.lld:pubmed
pubmed-article:19235854pubmed:languageenglld:pubmed
pubmed-article:19235854pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19235854pubmed:citationSubsetIMlld:pubmed
pubmed-article:19235854pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19235854pubmed:statusMEDLINElld:pubmed
pubmed-article:19235854pubmed:monthAprlld:pubmed
pubmed-article:19235854pubmed:issn1096-9071lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:MiyakawaYuzoYlld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:ShimazakiTomo...lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:HiroishiKazum...lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:ImawariMichio...lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:ItoTakayoshiTlld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:MorikawaKenic...lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:UchikoshiMana...lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:NozawaHisakoHlld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:InokuchiMomok...lld:pubmed
pubmed-article:19235854pubmed:authorpubmed-author:ShimozumaYuuYlld:pubmed
pubmed-article:19235854pubmed:copyrightInfo(c) 2009 Wiley-Liss, Inc.lld:pubmed
pubmed-article:19235854pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19235854pubmed:volume81lld:pubmed
pubmed-article:19235854pubmed:ownerNLMlld:pubmed
pubmed-article:19235854pubmed:authorsCompleteYlld:pubmed
pubmed-article:19235854pubmed:pagination619-27lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:meshHeadingpubmed-meshheading:19235854...lld:pubmed
pubmed-article:19235854pubmed:year2009lld:pubmed
pubmed-article:19235854pubmed:articleTitleInfection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C.lld:pubmed
pubmed-article:19235854pubmed:affiliationDepartment of Gastroenterology, Showa University School of Medicine, Tokyo, Japan.lld:pubmed
pubmed-article:19235854pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19235854pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19235854lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19235854lld:pubmed